Indian Scientists Pioneer AI-Driven Personalized Cancer Therapy

  //science-technology.news-articles.ne .. iven-personalized-cancer-therapy.html
  Published in Science and Technology on Wed, Nov 11th, 2025 by The Hans India

Indian Scientists Harness Artificial Intelligence for Personalized Cancer Therapy

In a groundbreaking development that blends cutting‑edge artificial intelligence (AI) with oncology, a consortium of Indian researchers has unveiled a suite of AI‑driven tools designed to customize cancer treatment plans for individual patients. The initiative, highlighted in a recent feature by The Hans India (https://www.thehansindia.com/life‑style/health/indian-scientists-tap-ai-for-personalised-cancer-therapy-1026468), underscores how data‑rich approaches can turn the tide in a field where “one size does not fit all.”

1. The Core Idea: From Big Data to Big Hope

Cancer is an inherently heterogeneous disease. Even within a single tumor type, variations in genetics, epigenetics, and micro‑environmental factors mean that patients respond differently to the same chemotherapy or radiation regimen. Traditional clinical protocols, largely based on population averages, often miss subtle biomarkers that could guide therapy.

The Indian team’s solution lies in harnessing the computational power of AI—specifically, deep learning and machine‑learning algorithms—to sift through massive datasets of tumor genomics, imaging, electronic health records, and clinical outcomes. By identifying patterns that escape conventional statistical analysis, the algorithms can predict which drugs are most likely to be effective for a particular tumor profile, what dose adjustments may be needed, and whether a patient is at risk of adverse reactions.

2. How the Technology Works

a. Data Integration and Pre‑processing

The first step involves collating data from multiple sources:

Pre‑processing steps standardize data formats, address missing values, and apply noise‑reduction techniques such as image denoising and batch‑effect correction for sequencing data.

b. Model Architecture

The platform combines two complementary AI architectures:

1. Convolutional Neural Networks (CNNs) for image‑based data, extracting spatial features from histology and radiology scans.
2. Graph Neural Networks (GNNs) for genomic data, representing the tumor’s mutational network as a graph where nodes are genes and edges capture functional interactions.

These models are then fused via a multimodal attention layer that weighs the relative importance of each data modality for a given patient.

c. Outcome Prediction

The final output is a probability distribution over a panel of approved chemotherapeutic agents, targeted therapies, and emerging immunotherapies. The AI not only indicates the most promising drug but also proposes dosage adjustments, potential combination regimens, and recommended monitoring protocols.

3. Validation in the Clinic

The article cites a recent retrospective study conducted at the All India Institute of Medical Sciences (AIIMS) in New Delhi. Involving 300 breast‑cancer patients, the AI model successfully predicted treatment response with an accuracy of 88% compared to 65% achieved by conventional risk scoring systems. Notably, the AI’s predictions led to a 12% reduction in unnecessary chemotherapy cycles, sparing patients from avoidable side effects.

Further, a collaboration with the Indian Institute of Technology (IIT) Bombay allowed the team to test the platform on lung‑cancer patients. The AI’s suggestions for immunotherapy combinations matched the outcomes of a prospective Phase‑II trial, underscoring the model’s clinical relevance.

4. Partnerships and Funding

The project is a joint effort between academia (AIIMS, IIT Bombay, and the Indian Institute of Science), industry partners (such as the AI startup Cure.ai and the biotech firm Bharat Biotech), and the National Cancer Grid (NCG). Funding has come from a mix of sources:

• Government Grants: The Department of Science and Technology (DST) awarded a Rs. 12 crore grant under its “AI for Health” program.
• Private Investment: Cure.ai contributed Rs. 8 crore in seed funding, aiming to commercialize the platform in 2025.
• International Collaborations: A partnership with the University of Oxford’s AI‑oncology lab has enabled data sharing and algorithm benchmarking.

5. Ethical, Legal, and Social Implications

While the AI approach promises significant gains, the article stresses the need for robust ethical safeguards:

• Data Privacy: All patient data are anonymized using blockchain‑based consent mechanisms, ensuring that individuals can withdraw consent at any time.
• Regulatory Approval: The platform is under review by the Central Drugs Standard Control Organization (CDSCO) for use as a clinical decision‑support tool.
• Bias Mitigation: Continuous audits are conducted to detect and correct algorithmic bias, especially concerning under‑represented demographic groups.

6. The Road Ahead

The Hans India feature highlights several future milestones:

1. Real‑time Integration: Developing a bedside application that automatically ingests new imaging or sequencing data as it becomes available.
2. Expanded Drug Libraries: Incorporating data from clinical trials and drug repurposing databases to widen the therapeutic arsenal.
3. Global Collaboration: Extending the model to datasets from African and Southeast Asian populations to improve generalizability.

7. Takeaway

Indian scientists are proving that AI can bridge the gap between precision oncology and personalized patient care. By turning vast, multidimensional datasets into actionable insights, this research offers a pathway to more effective, less toxic cancer treatments—one that could reshape the oncology landscape not just in India but worldwide.